Monoferric
Payments companies reported to CMS as associated with Monoferric. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Monoferric, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Monoferric
These are the largest totals companies reported as associated with Monoferric. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Myles Wolf | Chicago, IL | Nephrology (Internal Medicine) | $335,387.14 |
| Aryeh Shander | Englewood, NJ | Anesthesiology | $175,307.26 |
| Suresh Ratnam | Mcallen, TX | Medical Oncology | $146,609.14 |
| Steven Fein | Miami, FL | Hematology & Oncology | $115,535.20 |
| Christopher Chen | Tucson, AZ | Hematology & Oncology | $114,211.15 |
| Hassan Kaleem | Tulsa, OK | Hematology & Oncology | $102,197.31 |
| Joshua Strauss | Springfield, NJ | Hematology & Oncology | $89,784.66 |
| Ralph Boccia | Bethesda, MD | Hematology & Oncology | $83,862.83 |
| Hanny Al-Samkari | Boston, MA | Hematology & Oncology | $53,526.41 |
| Mohit Narang | Owing Mills, MD | Medical Oncology | $53,317.35 |
Prescribed Monoferric?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.